Insmed Inc(INSM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:52 PM ET (Korea 10/27 05:52)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.11 | Insider Own | 1.48% | Shs Outstand | 218.3M | Perf Week | -2.06% |
| Market Cap | 20.38B | Forward P/E | 114.53 | EPS next Y | 151.8% | Insider Trans | -13.04% | Shs Float | 215.2M | Perf Month | -20.79% |
| Enterprise Value | 19.97B | PEG | - | EPS next Q | -0.39 | Inst Own | 103.43% | Short Float | 6.41% | Perf Quarter | -10.37% |
| Income | -0.88B | P/S | 17.92 | EPS this Y | 75.5% | Inst Trans | -0.2% | Short Ratio | 5.17 | Perf Half Y | -31.36% |
| Sales | 1.14B | P/B | 26.89 | EPS next 5Y | - | ROA | -38.2% | Short Interest | 13.80M | Perf YTD | -46.37% |
| Book/sh | 3.47 | P/C | 17.57 | EPS past 3/5Y | -17.91% -16.32% | ROE | -87.22% | 52W High | -56.13% ($212.75) | Perf Year | -41.54% |
| Cash/sh | 5.31 | P/FCF | - | Sales past 3/5Y | 35.2% 29.83% | ROIC | -58.85% | 52W Low | 3.25% ($90.39) | Perf 3Y | 265.28% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.02% | Gross Margin | 82.78% | Volatility(W/M) | 2.91% 3.78% | Perf 5Y | 247.47% |
| Dividend TTM | - | EV/Sales | 17.55 | Sales Y/Y TTM | 185.76% | Oper. Margin | -71.43% | ATR (14) | 3.7 | Perf 10Y | 566.64% |
| Dividend Ex-Date | - | Quick Ratio | 3.4 | EPS Q/Q | 96.42% | Profit Margin | -76.94% | RSI (14) | 28.19 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.72 | Sales Q/Q | 296.11% | SMA20 | -7.45% ($100.84) | Beta | 0.84 | Target Price | $196.14 |
| Payout | - | Debt/Eq | 0.99 | Earnings | 2026/10/29 | SMA50 | -18.55% ($114.59) | Rel Volume | 1.26 | Prev Close | $93.39 |
| Employees | 1664 | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | 91.08% 7.58% | SMA200 | -26.33% ($126.69) | Avg Volume(3M) | 2.67M | Price | $93.33 |
| IPO | 1991/2/15 | Option/Short | Yes/Yes | Trades | 25149 | Volume | 3,366,133 | Change | -0.06% |
🔬 A U.S. biotech company whose core assets are therapeutics for chronic and rare respiratory diseases. Its flagship products are brensocatib, a new drug for non-cystic fibrosis bronchiectasis, and ARIKAYCE, a treatment for Mycobacterium avium complex (MAC) lung infection.
Over the past 1 year, on the lower side
56% below its 1-year high.
Traded more than usual. That is 126% of its average volume.
Next earnings report: October 29
3 days to go.
INSM has a sound balance sheet but weak earning power
Of every $100 in sales, $71.43 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +75.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,792. Peers typically go for $897.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +247.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 103.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #13 of 594 in the industry
Based on market cap of $20B.
FAQ
What kind of company is INSM?
INSM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INSM?
The market cap of INSM is approximately $20.4B, ranking 593 within its sector.
What is the 52-week high and low for INSM?
INSM has recorded a 52-week high of $212.75 and a low of $90.39.
